EMA Moves Ahead With Tailored Scientific Advice For Biosimilars
Follows Success Of Pilot Scheme That Offered Biosimilar Applicants Development Advice
Executive Summary
A European Medicines Agency pilot scheme offering tailored scientific advice on biosimilar development has been viewed by applicants as a “valuable opportunity” and the process will continue as part of regular operations, according to an agency report.